Immunotherapy toxicity management
Jump to navigation
Jump to search
This page is in process of being created.
Use of this site is subject to you reading and agreeing with the terms set forth in the disclaimer. If this is your first time visiting, we suggest you read the tutorial.
Have you noticed an error? Do you have an idea that will help the site grow to better meet your needs and the needs of many others? You are invited to contribute to the site.
Section editor | |
---|---|
Meghan Mooradian, MD Boston, MA |
Grading toxicity
CTCAE
- Common Terminology Criteria for Adverse Events (CTCAE) and Common Toxicity Criteria (CTC) - Adverse event grading for clinical trials
Diarrhea, colitis
Endocrinopathy
Fatigue
Liver, hepatic
Lung, pneumonitis
Kidney, renal
Neurologic
Ocular
Pancreas
Skin, dermatologic
Guidelines
- ESMO: Management of Toxicities from Immunotherapy: ESMO Clinical Practice Guidelines (2017)
- SITC: Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group
- Naidoo J, Page DB, Li BT, Connell LC, Schindler K, Lacouture ME, Postow MA, Wolchok JD. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann Oncol. 2015 Dec;26(12):2375-91. link to original article correction of Figure 2 PubMed
Evaluation
Endocrinopathy
- ACTH
- AM cortisol with cosyntropin stimulation test
- TSH
- FSH
- LH
- Prolactin
- Testosterone
Liver, hepatic
- Liver function tests (LFTs) or comprehensive metabolic panel (CMP)
- Hepatitis B & C serologies
- Liver/abdominal CT/MRI/ultrasound imaging
Kidney, renal
- BUN/creatinine, basic metabolic panel (BMP)
- Renal imaging (CT/MRI/ultrasound imaging)
- Urine sodium, urine urea, urine creatinine (for calculating FeNa and FeUrea)
- Kidney biopsy
Neurologic
- Electromyography (EMG)
Ocular
- Ophthalmology exam
Pancreas
- Amylase
- Lipase